Références

Evens R, Schmidt ME, Majić T, Schmidt TT. The psychedelic afterglow phenomenon: a systematic review of subacute effects of classic serotonergic psychedelics. Therapeutic Advances in Psychopharmacology. 2023;13:20451253231172254.
Majić T, Schmidt TT, Gallinat J. Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences. J Psychopharmacol. 2015;29:241-253.
Rickels K, Fox IL, Greenblatt DJ, Sandler KR, Schless A. Clorazepate and lorazepam: clinical improvement and rebound anxiety. American Journal of Psychiatry. 1988;145:312 - 317.
Halikas JA. Org 3770 (mirtazapine) versus trazodone: a placebo controlled trial in depressed elderly patients. HumPsychopharmacol. 1995;10:S125 - S133.
Fabre LF, Putman HP. Depressive symptoms and intellectual functionning in anxiety patients treated with clorazepate. Journal of Clinical Psychiatry. 1988;49:189 - 192.
Marie S. ‘Psychedelics are no magic pill’: the narrative and embodied dimensions of psychedelic integration in Denmark. Anthropology of Consciousness. 2025e12226.
Gezon LL. Community-based psychedelic integration and social efficacy: An ethnographic study in the Southeastern United States. Journal of Psychedelic Studies. 2025;9:8-19.
Gorman I, Nielson EM, Molinar A, Cassidy K, Sabbagh J. Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice. Front Psychol. 2021;12:645246.
Sanabria E, Tófoli LF. Integration or commodification? A critical review of individual-centered approaches in psychedelic healing. Journal of Psychedelic Studies. 2025
Lidz CW, Mulvey EP, Hoge SK et al. Factual sources of psychiatric patients’ perception of coercion in the hospital admission process. American Journal of Psychiatry. 1998;155:1254 - 1260.

Boite à outils

Prévention des risques post-expérience